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Summary
Isavuconazole is a novel antifungal drug approved for the treatment of adults with invasive aspergillosis and mucormycosis. While azoles as a class effect are known to 
| INTRODUCTION
Isavuconazole is a novel antifungal drug used for the treatment of invasive aspergillosis and mucormycosis in adults. The drug has been approved by the US and the European regulatory agencies in 2016.
While azoles as a class effect are known to prolong QTc interval, [1] [2] [3] clinical trials have shown that isavuconazole administration may shorten QTc interval in a dose-related manner. 4, 5 The QT interval is a measure of time in electrocardiograms (ECGs) and describes the duration of the cellular action potential. 6 Due to its variation with heart rate, the QT interval must be corrected before interpretation. Bazett's formula is most commonly applied for this purpose: the QT interval is divided by square root of the RR interval. The 
| PATIENTS AND METHODS
We observed 26 adult patients from 7 academic hospitals of maximum care (6 German, 1 Italian). Patients received isavuconazole for the treatment of invasive fungal infection (IFI) and, in 1 case, for prophylaxis due to QTc prolongation under fluconazole. Twelvechannel ECGs were performed before and during treatment.
Data on IFI, underlying disease, co-medication and electrolytes were obtained from electronic health records. Determining the QT interval adjusted to heart rate (QTc), the Bazett's correction formula (QTc = QT/√RR) was used for all calculations. Values depict the means ± standard deviation.
| RESULTS
A total of 26 patients treated with isavuconazole were observed.
Underlying conditions of the patients included haematological ma- 
| DISCUSSION
Isavuconazole is a second-generation azole antifungal approved for the treatment of invasive aspergillosis and mucormycosis. We here report on its capability of QTc shortening. Apart from one recent case report, these are the first data outside controlled clinical trials showing this effect. A contraindication for isavuconazole is thus a known familial short QT syndrome (SQTS), 11 a very rare autosomal dominant inherited channelopathy; published data include only a small number of families.
12
In a phase I randomised, double-blind trial, 148 healthy individuals received isavuconazole 400 and 600 mg (after 2-day loading dose).
Isavuconazole shortened the QTc interval in dose-related and plasma Isavuconazole is both a substrate and a moderate inhibitor of the CYP3A4 isoenzyme. 15, 16 This should be considered during administration of co-medication.
In our patient cohort, QT prolonging co-medications were mostly administered continuously before as well as during treatment with isavuconazole. QTc decreased when isavuconazole was given. One patient received tacrolimus for graft-vs-host disease following allogeneic haematopoietic stem cell transplantation from day 50 on. However, he showed a further decrease in QTc while on tacrolimus treatment (432-422 ms). Isavuconazole may often replace other triazoles, typically prolonging QT, due to microbiological failure or intolerable side effects; such switch within the azole class may enhance the observed effect of QTc shortening. However, we could not see differences in patients with or without prior treatment with azoles or other QT prolonging co-medication regarding QTc shortening by isavuconazole. We Among triazole antifungal agents, QTc shortening by isavuconazole is unique and so far has not been associated with untoward cardiovascular events. Knowledge about cardiac effects of isavuconazole will serve to better manage the use of concomitant medications. Consideration of SQTS is of minor importance as both SQTS and isavuconazole prescription are extremely rare issues.
